CLAIMS

1. Use of pentosan polysulfate or an acceptable salt thereof in the preparation of an intramuscular medicament for improving knee function in a human having bone marrow edema lesions in the knee as assessed by magnetic resonance imaging (MRI) and osteoarthritis 3-4 on the Kellgren-Lawrence scale in the knee so as to improve knee function by about 23% to about 89% as determined by the Lysholm Knee Score, wherein it has been determined that treatment of the knee of the human with a corticosteroid has failed.

2. The use of claim 1, wherein knee function is improved by about 23% to about 43%.

3. The use of claim 2, wherein knee function is improved by about 23% to about 35%.

4. The use according to any one of claims 1 to 3, wherein the pentosan polysulfate (PPS) is selected from the group consisting of: the sodium salt of pentosan polysulfate (NaPPS), the magnesium salt of pentosan polysulfate (MgPPS), the calcium salt of pentosan polysulfate (CaPPS), and the zinc salt of pentosan polysulfate (ZnPPS).

5. The use according to claim 4, wherein the pentosan polysulfate (PPS) is sodium pentosan polysulfate (NaPPS).

6. The use according to any one of claims 1 to 5, wherein the medicament comprises pentosan polysulfate or the acceptable salt thereof in an effective amount of about 1 to 2 mg/kg of the human per dose or an effective amount of between about 25 mg and 300 mg as a fixed dose.

7. The use according to any one of claims 1 to 6, wherein the medicament comprises pentosan polysulfate or the acceptable salt thereof in an effective amount of

about 2 mg/kg of the human per dose or an effective amount of about 150 mg as a fixed dose.